Quick Answer
Transcode Therapeutics, Inc. reported Net Income of -$16.75 million for fiscal year 2024.
Transcode Therapeutics, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Net Income | -$16.75M +9.7% |
-$18.55M -5.6% |
-$17.56M -156.7% |
-$6.84M -192.0% |
-$2.34M | — |
| Diluted EPS | -$47.14 +98.6% |
-$3419.01 -215.8% |
-$1082.79 -133577.8% |
-$0.81 -58.8% |
-$0.51 | — |
| Total Assets | $7.29M +41.1% |
$5.17M -31.9% |
$7.59M -66.9% |
$22.94M +2073.5% |
$1.06M | — |
| Cash and Equivalents | $5.81M +110.0% |
$2.77M -44.3% |
$4.97M -76.1% |
$20.83M +2415.2% |
$828.0K | — |
| Stockholders Equity | -$2.02M -223.0% |
$1.64M -49.4% |
$3.24M -84.1% |
$20.40M +698.7% |
-$3.41M -207.1% |
-$1.11M |
| R&D Expense | $9.71M -20.9% |
$12.26M +19.9% |
$10.23M +271.6% |
$2.75M +868.1% |
$284.5K | — |
| Operating Income | -$15.66M +19.4% |
-$19.42M -4.2% |
-$18.63M -202.9% |
-$6.15M -746.6% |
-$726.6K | — |
| Shares Outstanding | 1.03M +5312.3% |
19,014 +17.2% |
16,222 -99.9% |
12.90M +178.3% |
4.64M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.86M | -109.2% | -13.6% |
| Diluted EPS | September 30, 2025 | -$5.82 | +96.0% | -13.5% |
| Total Assets | September 30, 2025 | $5.23M | +32.8% | -36.8% |
| Cash and Equivalents | September 30, 2025 | $2.84M | +51.2% | -61.5% |
| Stockholders Equity | September 30, 2025 | $1.43M | -13.7% | -76.8% |
| R&D Expense | September 30, 2025 | $3.16M | +157.5% | +23.2% |
| Operating Income | September 30, 2025 | -$4.56M | -110.6% | -8.1% |
| Shares Outstanding | September 30, 2025 | 833,683 | -95.2% | +0.0% |
- Transcode Therapeutics, Inc. reported Net Income of -$16.75 million for fiscal year 2024.
- Transcode Therapeutics, Inc. showed an increase of +9.7% in Net Income compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported Diluted EPS of $47.14 per share (loss) for fiscal year 2024.
- Transcode Therapeutics, Inc. showed an increase of +98.6% in Diluted EPS compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported Total Assets of $7.29 million for fiscal year 2024.
- Transcode Therapeutics, Inc. showed an increase of +41.1% in Total Assets compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported Cash and Equivalents of $5.81 million for fiscal year 2024.
- Transcode Therapeutics, Inc. showed an increase of +110.0% in Cash and Equivalents compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported Stockholders Equity of -$2.02 million for fiscal year 2024.
- Transcode Therapeutics, Inc. showed a decrease of -223.0% in Stockholders Equity compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported R&D Expense of $9.71 million for fiscal year 2024.
- Transcode Therapeutics, Inc. showed a decrease of -20.9% in R&D Expense compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported Operating Income of -$15.66 million for fiscal year 2024.
- Transcode Therapeutics, Inc. showed an increase of +19.4% in Operating Income compared to the prior fiscal year.
- Transcode Therapeutics, Inc. reported Shares Outstanding of 1.03 million shares for fiscal year 2024.
- Transcode Therapeutics, Inc. showed an increase of +5312.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: